Sugi Predict

Sugi Predict / Targets / MAN2B1

MAN2B1

Lysosomal alpha-mannosidase · O00754 · MAN2B1 on Sugi Atlas →

1,067 patent compounds predicted against MAN2B1, 680 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL25581542 SCHEMBL25581542 0.71 6/20
SCHEMBL25581551 SCHEMBL25581551 0.71 6/20
SCHEMBL25581578 SCHEMBL25581578 0.71 6/20
SCHEMBL25581620 SCHEMBL25581620 0.71 6/20
SCHEMBL25581633 SCHEMBL25581633 0.71 6/20
SCHEMBL25581637 SCHEMBL25581637 0.71 6/20
SCHEMBL25581539 SCHEMBL25581539 0.64 6/20
SCHEMBL25581518 SCHEMBL25581518 0.64 6/20
SCHEMBL25581527 SCHEMBL25581527 0.64 6/20
SCHEMBL25581585 SCHEMBL25581585 0.64 6/20
SCHEMBL25581596 SCHEMBL25581596 0.64 6/20
SCHEMBL25581601 SCHEMBL25581601 0.64 6/20
SCHEMBL25581660 SCHEMBL25581660 0.64 6/20
SCHEMBL25581401 SCHEMBL25581401 0.57 6/20
SCHEMBL25581515 SCHEMBL25581515 0.56 6/20
SCHEMBL16497851 SCHEMBL16497851 0.52 6/20
SCHEMBL16497852 SCHEMBL16497852 0.52 6/20
SCHEMBL25581410 SCHEMBL25581410 0.50 5/20
SCHEMBL1818742 SCHEMBL1818742 0.61 4/20
SCHEMBL25581419 SCHEMBL25581419 0.57 4/20

Clinical trials — most relevant to MAN2B1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA PHASE1/PHASE2ACTIVE_NOT_RECRUITING
High-Dose Ambroxol in GBA1-Related Parkinson PHASE1/PHASE2UNKNOWN
Biomarker for Mannosidosis Disease (BioMannosidosis) nanWITHDRAWN
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Registry Gangliosidoses nanUNKNOWN
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease nanCOMPLETED
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease nanRECRUITING
Italian Anderson Fabry Disease Cardiovascular Registry nanRECRUITING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease nanCOMPLETED
Cellular and Molecular Mechanisms Governing Bone Marrow Stem Cells in Gaucher Disease nanCOMPLETED
Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia nanUNKNOWN
Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1) nanCOMPLETED
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity nanCOMPLETED
Biomarker for Patients With Fabry Disease (BioFabry) nanWITHDRAWN
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
Biomarker for Hurler Disease (BioHurler) nanWITHDRAWN
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease nanNO_LONGER_AVAILABLE
The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease nanCOMPLETED
Screening of Fabry Disease in Patients With GI Symptoms nanUNKNOWN
Psychological Concomitants of Morquio A Syndrome - Longitudinal Effects of Enzyme Replacement Therapy (The MAPLE Study) nanCOMPLETED
Characterization of the Patient Population With Galactosialidosis nanCOMPLETED
Screening of Lysosomal Storage Disorders Diseases in Minority Groups nanUNKNOWN
Biomarker for Gaucher Disease: BioGaucher (BioGaucher) nanWITHDRAWN
The Natural History of Sialidosis Type I nanRECRUITING
Unrelated Donor BMT for Treatment of Patients With PGK Deficiency nanCOMPLETED
Biomarkers Related to Bone in Pediatric Gaucher Disease nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MAN2B1 binder may also engage these)

ProteinNameSimilarity
O46432 — 1.000 O46432 →
Q60HE9 — 1.000 Q60HE9 →
Q8VHC8 — 0.998 Q8VHC8 →
Q29451 — 0.992 Q29451 →
O09159 — 0.990 O09159 →
P27046 — 0.974 P27046 →
P79403 — 0.971 P79403 →
GAA Lysosomal alpha-glucosidase 0.971 landscape →
Q5RDJ3 — 0.970 Q5RDJ3 →
Q4R4N7 — 0.969 Q4R4N7 →
P28494 — 0.969 P28494 →
Q12891 — 0.969 Q12891 →
GANAB Neutral alpha-glucosidase AB 0.968 landscape →
Q8BHN3 — 0.967 Q8BHN3 →
Q28949 — 0.967 Q28949 →
Q9MYM4 — 0.966 Q9MYM4 →
O97524 — 0.966 O97524 →
O54782 — 0.966 O54782 →
Q5R7A9 — 0.966 Q5R7A9 →
Q8SQG8 — 0.965 Q8SQG8 →
P70699 — 0.965 P70699 →
O18835 — 0.964 O18835 →
Q5RFL1 — 0.964 Q5RFL1 →
Q8LPJ3 — 0.964 Q8LPJ3 →
Q5R5N6 — 0.963 Q5R5N6 →
Q60HF8 — 0.963 Q60HF8 →
FUCA2 Plasma alpha-L-fucosidase 0.963 landscape →
O89023 — 0.963 O89023 →
MAN2B2 Epididymis-specific alpha-mannosidase 0.963 landscape →
FUCA1 Tissue alpha-L-fucosidase 0.963 landscape →